viewCytoDyn Inc.

CytoDyn says that independent safety review of Phase 3 leronlimab trials found no concerns

The review was conducted by the Data Safety Monitoring Committee (DSMC), which looked at compiled safety data from 149 patients enrolled in the trial

CytoDyn Inc. -
Leronlimab is being studied as a potential treatment for COVID-19

CytoDyn Inc (OTCQB:CYDY) announced Tuesday that an independent safety review of its ongoing Phase 3 clinical trial of leronlimab found no concerns and recommended the trial continue.

The review was conducted by the Data Safety Monitoring Committee (DSMC), which looked at compiled safety data from 149 patients enrolled in the trial.

Leronlimab is being studied as a potential treatment for the coronavirus (COVID-19). The treatment was previously granted Fast Track designation by the US Food and Drug Administration for the treatment of HIV in combination with highly active antiretroviral therapy (HAART), and for metastatic triple-negative breast cancer, a rare variety which doesn’t respond to some treatments. 

READ: CytoDyn says FDA seeks more information to complete a review for leronlimab as a combination therapy for HIV patients

Vancouver, Washington-based CytoDyn has 169 enrolled patients in its Phase 3 study and will conduct a full interim analysis once 195 patients are enrolled, as provided in the trial’s protocol, it said in a release Tuesday.

In a statement, CEO Nader Pourhassan thanked the DSMC for its “diligence, guidance and support.

“We are grateful to be less than 30 patients away from our planned interim analysis enrollment goal, and we look forward to sharing those interim efficacy results as soon as possible.”  

The Phase 3 randomized, double blind, placebo controlled, adaptive design multicenter two arm study is designed to evaluate the safety and efficacy of leronlimab in patients with severe or critical symptoms of respiratory illness caused by COVID-19. Patients are randomized 2:1 (two leronlimab: one placebo) to receive weekly doses of 700 milligrams leronlimab or placebo through subcutaneous injection. 

Chief scientific officer Jacob Lalezari added that the firm “eagerly awaits” the results of the pending full interim analysis of CD12, as well as the complete safety and efficacy results from CD10, a recently completed study of patients with mild to moderate COVID-19 illness.

“We are very pleased the DSMC reported no safety concerns in CD12, a population with very severe illness and comorbidities at study entry,” Lalezari said in a statement.

“We believe these results will provide compelling proof of efficacy and soon provide the world with a broadly effective therapeutic option for this devastating pandemic.”

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas


Quick facts: CytoDyn Inc.

Price: 3.395 USD

Market: OTCQB
Market Cap: $1.93 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...


CytoDyn addresses WSJ & SeekingAlpha articles, calls on investors to pay...

CytoDyn Inc. (OTCQB:CYDY) CEO Nader Pourhassan addresses the recent articles published by the Wall Street Journal and SeekingAlpha, in regards to its participation in Operation Warp Speed. Pourhassan says shareholders should pay attention to the group's fundamentals, adding to 'only buy the...

4 weeks, 1 day ago

2 min read